Recently, BAY-876, a highly selective GLUT1 inhibitor, was recently reported to inhibit the tumorigenesis of ovarian cancer cells in vivo by blocking glycolysis and growth (36). This evidence concerns the gene SLC2A1 and ovarian cancer.